Autonomous Blood Drawing Optimization and Performance Testing
Autonomous Blood Drawing Optimization and Performance Testing
The purpose of this pre-market clinical study is to evaluate the performance (efficacy) and safety of an autonomous blood drawing device (Venipuncture Device).
The study consists of several phases (A, B1, B2, B3, C1, C2, C3, 0).
Phase B1 is a confirmatory, Pivotal Clinical Study, required for regulatory approval, in which non-inferiority should be demonstrated in comparison to manual blood drawing.
Phases A, B2, B3, C1, C2, C3 are all exploratory studies, in which the technology and usability is further improved and tested. Phase 0 is an exploratory study for non-invasive technology testing (for example for improvement of ultrasound detection).
The study locations are outpatient blood drawing departments, in which patients are included as subjects. Additionally, in Phase A and C1, a small number of volunteers can be included in a non-hospital site (Vitestro Site).
Inclusion Criteria:
• Age ≥16 years.
Exclusion Criteria:
The following contra-indications / exclusion criteria are respected per arm:
In case the test subject has a suitable contralateral arm, the subject can be included in this study. In Study Phase B2 or B3, venipunctures are performed in both arms. Patients who have a contra-indication in one arm are excluded from the Phase B2 and Phase B3 study.
luuk.giesen@vitestro.com+31 30 200 45 51
jeroen.roest@vitestro.com+31 30 200 45 51
Copenhagen, 2400, Denmark
nicolai.albrechtsen@regionh.dk+45 38 63 50 00
Dordrecht, South Holland 3318 AT, Netherlands
mads.nybo@rsyd.dk+45 20 55 39 52
m.deckers@olvg.nl+31 20 510 89 51
r.dejonge1@amsterdamumc.nl+31 20 566 4851
m.fouraux@resultlaboratorium.nl+31 78 654 1810
t.van.holten@antoniusziekenhuis.nl+31 88 320 7190
luuk.giesen@vitestro.com+31 30 200 4551